Part of the National Clinical Trials Network, the Alliance for Clinical Trials in Oncology is a leader in advancing cancer research, uniting more than 25,000 cancer specialists at 115 main institutions and 1,400 affiliates across the U.S. and Canada.
Alliance for Clinical Trials in Oncology
Loading...
Alliance Announces FDA Acceptance of Supplemental Biologics License Application Supported by Results from the Phase III ATOMIC Trial for Patients with Stage III dMMR Colon Cancer - read more: https://bit.ly/ATOMIC-FDA #NCI #NCTN #CancerResearch #ColonCancer
Now enrolling! BCG (a bladder immunotherapy) is standard for non-muscle invasive bladder cancer. For cancer returned after BCG, the Alliance A032103 (GAIN) trial tests adding gemcitabine—a chemo drug—to BCG to prevent recurrence. Learn more: https://bit.ly/Alliance-GAIN-BCG #BladderCancer
Dr. Brad McGregor of Dana-Farber Cancer Institute leads Alliance A032201 (STRIKE) to see if adding the tivozanib to the standard treatment of immunotherapy after surgery helps patients with high-risk renal cell cancer. Learn more: https://bit.ly/Alliance-A032201 #NCI #PCSM #clinicaltrials
Twitter: Trial Tuesday! Drs. RanaMcKayMD UC San Diego Health and Misha Beltran of Dana-Farber Cancer Institute co-lead A032102/PREDICT evaluating if genetic testing helps determine the best treatment regimen for men with metastatic prostate cancer. Learn more: https://bit.ly/Alliance-A032102 #PCsm
Now enrolling! Drs. Thomas Hope of UCSF Helen Diller Family Comprehensive Cancer Center and Deaglan McHugh of Memorial Sloan Kettering Cancer Center lead Alliance A032304 (RECIPROCAL), studying targeted radiation therapy to minimize side effects in prostate cancer https://bit.ly/AllianceA032304
New trial! The Alliance has a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma. Visit https://bit.ly/CLL-SLL to learn about Alliance A042302 led by Dr. Jennifer R. Brown of Dana-Farber Cancer Institute
Dr. Ugonma Chukwueke of Dana-Farber Cancer Institute leads a new Alliance trial exploring if adding a targeted medicine called vorasidenib to the usual treatment can help people with newly diagnosed IDH mutated grade 3 astrocytoma, a type of brain cancer. https://bit.ly/Brain2026 #clinicaltrials
New findings of an Alliance Foundation Trials study show combining immunotherapy and chemotherapy before surgery improves outcomes for some patients with locally advanced non-small cell lung cancer, according to the results of AFT-46/CHIO3 published in Lung Cancer. #LCSM https://bit.ly/AFT46
Alliance for Clinical Trials in Oncology
Important news from #ASCO26: AFT-47 led by Dr. Alicia Morgans from Dana-Farber News found hormone therapy darolutamide was associated with significantly less cognitive decline than enzalutamide for prostate cancer. Read the full update Alliance for Clinical Trials in Oncology https://bit.ly/4xBNGKl
New research by @danafarber.bsky.social’s Dr. Suzanne George in JNCI Cancer Spectrum describes the user-centered development and pilot implementation of the Participant Engagement Portal (PEP) by @alliance-org.bsky.social to improve information flow. Read more: bit.ly/43w3Res
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Dana-Farber News
AbstractBackground. Digital tools may enhance clinical trial engagement by improving information flow and supporting participant-directed communication. Th
